Advertisement

Studies of the Mechanism of Prevention of Fatty Livers by the Administration of Adenosine Triphosphate

  • D. E. Hyams
  • A. Bizzi
  • A. Lietti
  • S. Garattini
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 4)

Abstract

Administration of large doses of adenosine triphosphate (ATP) can protect rats against the fatly liver produced by ethionine1,2,3 carbon tetrachloride3 (CCl4), azaserine3, ethanol4 and puromycin5. In considering the possible mechanisms involved in this protection, Hyams et al 3. suggested that suppression of free fatty acid (FFA) mobilisation was a major factor, but the possibility that hypothermia played a part, at least in the case of CCl4 toxicity, could not be excluded.

Keywords

Adipose Tissue Free Fatty Acid Fatty Liver Adenosine Triphosphate Plasma Free Fatty Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Farber, E., Lombardi, B., and Castillo, A.E. Lab. Invest., 12: 873 (1963)PubMedGoogle Scholar
  2. 2.
    Farber, E., Shull, K.H., Villa-Trevino, S., Lombardi, B. and Thomas, H. Nature, 203: 34. (1964)PubMedCrossRefGoogle Scholar
  3. 3.
    Hyams, D.E., Taft, E.B., Drummey, G.D. and Isselbacher, K.J. Lab. Invest., 16: 604. (1967)PubMedGoogle Scholar
  4. 4.
    Hyams, D.E., and Isselbacher, K.J. Nature, 204: 1196. (1964)PubMedCrossRefGoogle Scholar
  5. 5.
    Hyams, D.E. Unpublished observations.Google Scholar
  6. 6.
    Dole, V.P. J. Clin. Invest., 35: 150. (1956)CrossRefGoogle Scholar
  7. 7.
    Wieland, O. Biochem. Zschr. 329: 313. (1957)PubMedGoogle Scholar
  8. 8.
    Huggett, A. St. G., ana Nixon, D.A. Biochem. J. 66: 12P (1957)Google Scholar
  9. 9.
    Van Handel, E., and Zilversmit, D.B. J. Lab. Clin. Med., 50: 152. (1957)Google Scholar
  10. 10.
    Folch, J., Lees, H., and Sloane Stanley, G.H. J. Biol. Chem. 226: 497. (1957)Google Scholar
  11. 11.
    Recknagel, R.O. Pharmacol. Revs., 19: 145. (1967)Google Scholar
  12. 12.
    Bizzi, A., Tacconi, M.T., Veneroni, E., & Garattini, S. Nature, 209: 1025. 1966)PubMedCrossRefGoogle Scholar
  13. 13.
    Bizzi, A., Garattini, S., & Veneroni, E. Brit. J. Pharmacol., 25: 187 (1965)PubMedGoogle Scholar
  14. 14.
    Biazi, A., Codegoni, A.M., & Garattini, S. II Farmaco, 22: 709. 1967)Google Scholar
  15. 15.
    Carlson, L.A., and Orö, L. — quoted by Carlson L.A. and Bally P.R. — see 16.Google Scholar
  16. 16.
    Carlson, L.A., and Bally P. R. In Handbook of Physiology. Section 5: Adipose tissue; ed. Henold, A.B., and Cahill, G.F., Jr., p.557. Washington, D.C., American Physiological Society. (1965)Google Scholar
  17. 17.
    Paoletti, R., personal communication.Google Scholar
  18. 18a.
    Green, H.H. and Stoner, H.B. Biological Actions of the Adenine Nucleotides, p.39. London — H.K. Lewis & Co. Ltd. (1950)Google Scholar
  19. 18b.
    Green H.N. & Stoner, H.B. op. cit., p.98.Google Scholar
  20. 18c.
    Green H.N. & Stoner, H.B. op. cit., pp.28, 68 et. seq.Google Scholar
  21. 18d.
    Green H.N. & Stoner, H.B. op. cit., p.65.Google Scholar
  22. 18e.
    Green H.N. & Stoner, H.B. op. cit., pp. 35 & 118.Google Scholar
  23. 19.
    Randle, P.J., Garland, P.B., Hales, C.N., & Newsholme, E.A. Lancet, 1: 785 (1963)PubMedCrossRefGoogle Scholar
  24. 20.
    Hrdina, P., Bonaccorsi, A., & Garattini, S. Surop. J. Pharmacol., 1: 99 (1967)CrossRefGoogle Scholar
  25. 21.
    Larson, H.E.J and Plaa, G.L. J. Pharmacol. Exp. Therap., 147: 103. (1965)Google Scholar

Copyright information

© Plenum Press 1969

Authors and Affiliations

  • D. E. Hyams
    • 1
  • A. Bizzi
    • 1
  • A. Lietti
    • 1
  • S. Garattini
    • 2
  1. 1.Chesterton HospitalCambridgeEngland
  2. 2.Mario Negri Institute of Pharmacological ResearchMilanItaly

Personalised recommendations